Oncology

PB (CT) 4010

PB (CT) 4010 is a biosimilars humanized monoclonal antibody used for the treatment of various cancers as an angiogenesis incubator. PB (CT) 4010 inhibits a vascular endothelial growth factor that stimulates the formation of new blood vessels.

PB (CT) 4020

PB (CT) 4020 is a biosimilar monoclonal human antibody that reverses the effects of an overactive HER2 receptor, the HER2 gene (also known as HER2/new and ErbB2 gene) which is amplified in 20-30% of early stage breast cancers. PB (CT) 4020 works by binding to the domain IV of the extracellular segment of the HER2 Neu receptor, for example to a specific antigen (HER2) on the surface of breast cancer cells to inhibit cell proliferation and growth.

Company Presentation 2018

Company Presentation 2016

Company Presentation 2014

Company Presentation 2012

Meet Us At

Connect with us

Paras Biopharmaceuticals
Finland Oy
,

Kiviharjunlenkki 10, OULU,
FI-90220 Finland

P: +358 442709462

Dr Ashesh Kumar
E: kumar.ashesh@parasbiopharma.com
P: +358 (0) 400207380

Dr Upendra Khurana
E: upendra.khurana@parasbiopharma.com
P:+358 (0) 449783160

Dr Mark Jackson
E: mark.jackson@parasbiopharma.com
P:+358 (0) 442905993

Skype: Paras.Finland